Human brain immune cells (microglia and astrocytes) constitutively express substance P's receptor NK-1R, and substance P amplifies their inflammatory and neurotoxic responses to bacterial infection.
Constitutive NK-1R expressionHuman microglia and astrocytes naturally express full-length substance P receptors at robust levels, meaning the brain is permanently primed to respond to this inflammatory neuropeptide.
What the researchers found
Human microglia and astrocytes constitutively express robust levels of the full-length neurokinin-1 receptor (NK-1R) isoform. Bacterial pathogens further elevated NK-1R expression in astrocytes. Substance P activated NF-κB signaling in microglia and augmented inflammatory cytokine release and neurotoxic mediator production by astrocytes in response to bacterial pathogens.
These findings were confirmed across multiple systems: nonhuman primate brain explants, primary human microglia and astrocytes, and immortalized human glial cell lines, using RT-PCR, immunoblotting, immunofluorescence, flow cytometry, ELISA, and neuronal toxicity assays. Previous work by the same group showed NK-1R antagonists could limit neuroinflammatory damage in bacterial meningitis models.
Why it matters
Bacterial meningitis can cause devastating brain damage, much of it from the body's own inflammatory response rather than the bacteria themselves. This study identifies the substance P/NK-1R pathway as a key amplifier of this damaging neuroinflammation. Since NK-1R antagonists (substance P blockers) already exist as approved drugs for other conditions, there's a clear path toward repurposing them to protect the brain during severe infections.
How the study worked
Researchers used multiple complementary techniques — RT-PCR, immunoblot analysis, immunofluorescent microscopy, and flow cytometry — to characterize NK-1R expression in nonhuman primate brain tissue, primary human microglia and astrocytes, and immortalized human glial cell lines. Functional responses to substance P were assessed through NF-κB nuclear translocation analysis, ELISA for inflammatory cytokines, and neuronal cell toxicity assays following exposure to bacterial pathogens.
What this study cannot tell us
All experiments were conducted in vitro or ex vivo using cell cultures and brain tissue explants, not in living patients. The exact downstream signaling pathways beyond NF-κB were not fully mapped. The study focused on bacterial infections and may not generalize to viral or autoimmune neuroinflammation. No clinical trial of NK-1R antagonists for meningitis has been conducted.
How to read the evidence
This is a mechanistic in vitro/ex vivo study using human and primate cells and tissue. It provides strong molecular evidence for the substance P/NK-1R pathway in neuroinflammation but has not been validated in clinical settings.
When this study was published
Published in 2017, this study established foundational knowledge about substance P signaling in human brain immune cells. The NK-1R antagonist approach for neuroinflammation remains an active area of preclinical research.
The bigger picture
The role of neuropeptides in neuroinflammation is an expanding field that bridges neuroscience and immunology. This study establishes that substance P doesn't just transmit pain in the brain — it actively drives destructive inflammation through glial cells. Combined with the group's earlier finding that NK-1R antagonists limit meningitis damage, this work builds a case for targeting neuropeptide signaling as a neuroprotective strategy in CNS infections and potentially other neuroinflammatory conditions.
Questions still open
- Could NK-1R antagonists be used as adjunct therapy alongside antibiotics to reduce brain damage in bacterial meningitis patients?
- Does the substance P/NK-1R pathway contribute to neuroinflammation in non-infectious conditions like Alzheimer's disease or multiple sclerosis?
- What specific downstream mediators does substance P-induced NF-κB activation produce in human microglia?
Common questions
What is substance P and what role does it play in the brain?
Are there already drugs that block substance P's effects?
Read the original research
Human microglia and astrocytes constitutively express the neurokinin-1 receptor and functionally respond to substance P.
Journal of neuroinflammation, 14(1), 245
Citation
Burmeister, Amanda R; Johnson, M Brittany; Chauhan, Vinita S; Moerdyk-Schauwecker, Megan J; Young, Ada D; Cooley, Ian D; Martinez, Alejandra N; Ramesh, Geeta; Philipp, Mario T; Marriott, Ian. (2017). Human microglia and astrocytes constitutively express the neurokinin-1 receptor and functionally respond to substance P.. Journal of neuroinflammation, 14(1), 245. https://doi.org/10.1186/s12974-017-1012-5